A fingerprint map construction method and fingerprint map of Xihuang capsule
Through ultrasonic extraction of methanol-chloroform-phosphoric acid solution and high-performance liquid chromatography analysis, the fingerprint map of Xihuang capsule was constructed, which solved the problem of insufficient quality detection of Xihuang capsules in the existing technology, and achieved a comprehensive and objective evaluation of the quality of Xihuang capsules. , improves its safety and efficacy.
Patent Information
- Application Number
- CN202211281103.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-10-19
AI Technical Summary
The prior art cannot effectively control the overall component information of Xihuang Capsules, resulting in fewer quality detection methods, and cannot well control the quality of Xihuang Capsules, affecting clinical efficacy.
The test solution of Xihuang Capsules was prepared by ultrasonic extraction method of methanol-chloroform-phosphoric acid solution. Combined with high-performance liquid chromatography analysis, the fingerprint of Xihuang Capsules was constructed, and the control fingerprint was generated through the chromatogram similarity evaluation system, and the control fingerprint was identified and marked. Each has a peak to determine the chemical composition of Xihuang Capsules.
It has achieved a comprehensive and objective evaluation of the quality of Xihuang Capsules, improved the precision and stability of quality control, and ensured its safety and efficacy. It is of great significance to the identification of ingredients and the formulation of quality standards of Xihuang Capsules.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of quality control management of compound Chinese medicine preparations, and specifically relates to a fingerprint spectrum construction method and a fingerprint spectrum of Xihuang Capsules. Background Art
[0002] Xihuang Capsule originated from the ancient prescription Xihuang Pill in the "Surgery Collection" by Wang Hongxu, a famous doctor in the Qing Dynasty. It is refined by modern technology from four Chinese medicines: bezoar, musk, frankincense, and myrrh. The main ingredients of the prescription are bezoar, which can clear the heart, reduce fever and resolve phlegm, open the orifices, and disperse swelling. The aromatic and pungent properties of musk can clear the meridians, disperse blood stasis and reduce swelling. Frankincense cooperates with other medicines to promote blood circulation, remove blood stasis, reduce swelling and relieve pain. The whole prescription cooperates to clear away heat and detoxify, promote blood circulation and remove blood stasis, and reduce swelling. At present, it is often used clinically to treat breast fibroids, breast cancer, cervical lymph node tuberculosis, lymphadenitis, osteomyelitis, appendicitis, suppurative dermatitis, multiple abscesses, bacteremia, acute suppurative infection and malignant tumors.
[0003] Currently, there are few quality inspection methods for Xihuang Capsules, and most of them are studies on the ingredients of single herbs in the prescription, which cannot reflect the overall ingredient information of Xihuang Capsules, so its quality cannot be well controlled. Summary of the invention
[0004] The purpose of the present invention is to solve the deficiencies of the prior art and to provide a fingerprint spectrum construction method and fingerprint spectrum of Xihuang Capsule. The method can accurately, clearly and objectively evaluate the quality of Xihuang Capsule, and has an important role and value for controlling the quality of Xihuang Capsule and improving and ensuring clinical efficacy.
[0005] The present invention is achieved through the following technical solutions:
[0006] A method for constructing a fingerprint of Xihuang Capsule comprises the following steps:
[0007] S1. Take the contents of Xihuang Capsules, add methanol-chloroform-phosphoric acid solution, and perform ultrasonic extraction to obtain the Xihuang Capsules test solution;
[0008] S2, take bile acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone and bisabolone, dissolve in ethanol, and obtain mixed standard solution 1; take quassin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid and sandarac pimaric acid, dissolve in methanol, and obtain mixed standard solution 2;
[0009] S3, injecting the Xihuang Capsule test solution, mixed standard solution 1 and mixed standard solution 2 into a high performance liquid chromatograph, respectively, performing chromatographic analysis, and recording corresponding chromatograms;
[0010] S4. Construct a fingerprint of Xihuang Capsule according to the chromatogram of the Xihuang Capsule test solution and the chromatograms of the mixed standard solution 1 and the mixed standard solution 2 obtained in S3.
[0011] Preferably, in S1, in the methanol-chloroform-phosphoric acid solution, the volume ratio of methanol to chloroform is 1:3, and the volume ratio of the total amount of methanol and chloroform to phosphoric acid is 100:0.2.
[0012] Preferably, in S3, the chromatographic column used in the high performance liquid chromatograph is Hypersil C18 ODS.
[0013] Preferably, in S3, the mobile phase used in the chromatographic analysis is methanol-0.08% phosphoric acid-acetonitrile.
[0014] Furthermore, in S3, a UV-visible absorption detector is used for multi-wavelength switching detection during chromatographic analysis, and the detection wavelengths are: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm.
[0015] Further, in S3, during the chromatographic analysis, the gradient elution program is: 0-15 min methanol volume 54%→65%, 0.08% phosphoric acid volume 36%→25%; 15-45 min methanol volume 65%→78%, 0.08% phosphoric acid volume 25%→12%; 45-55 min methanol volume 78%→80%, 0.08% phosphoric acid volume 12%→10%; 55-65 min methanol volume 80%→82%, 0.08% phosphoric acid volume 10%→8%; 65-75 min methanol volume 82%→84%, 0.08% phosphoric acid volume 8%→6%; 75-90 min methanol volume 84%→86%, 0.08% phosphoric acid volume 6%→4%; 90-100 min methanol volume 86%→88%, 0.08% phosphoric acid volume 4%→2%; 100-110min methanol volume 88%→90%, 0.08% phosphoric acid volume 2%→0%.
[0016] Preferably, S4 specifically comprises: importing the chromatograms of different batches of Xihuang Capsule test solutions into the Chinese medicine chromatographic fingerprint similarity evaluation system 2004A, selecting the chromatographic peaks existing in the chromatograms of different batches of Xihuang Capsule as common peaks, generating a reference fingerprint of Xihuang Capsule by using the average value calculation method, calculating the relative retention time and relative peak area of each common peak; and marking the chemical composition of each common peak in the reference fingerprint according to the retention time of the chromatograms of the mixed standard solution 1 and the mixed standard solution 2; using the reference fingerprint R to generate a common chromatographic peak pattern, analyzing and calculating the similarity between the chromatograms of each batch of Xihuang Capsule and the common chromatographic peak, and confirming the reliability of the chromatograms of each batch of Xihuang Capsule test solution;
[0017] The chromatogram of the Xihuang Capsule test solution obtained in S3 was compared with the chromatograms of the mixed standard solution 1 and the mixed standard solution 2, and peak No. 3 in the chromatogram was identified as mysabolone; peak No. 4 was sandarapimaric acid; peak No. 8 was quassin; peak No. 10 was musk ketone; peak No. 11 was 11-carbonyl-β-boswellic acid; peak No. 12 was 11-carbonyl-β-acetylboswellic acid; peak No. 13 was acetyl-11α-methoxy-β-boswellic acid, and the fingerprint of Xihuang Capsule was obtained.
[0018] The fingerprint of Xihuang Capsule was constructed by the described method.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] Traditional Chinese medicine fingerprints can characterize the characteristics of the main chemical components of drugs in an overall and macroscopic manner. It is currently recognized as one of the most suitable means for quality control of chemical components of Chinese medicinal materials and Chinese patent medicines. Traditional Chinese medicine fingerprints combined with modern analytical technology use chemical groups that can reflect the material basis of the efficacy of traditional Chinese medicine to comprehensively evaluate the quality of traditional Chinese medicine, and are widely used in the formulation of traditional Chinese medicine quality standards. Based on this, the present invention provides a method for constructing a fingerprint of Xihuang Capsules. The present invention conducts experimental investigations on different extraction methods and extraction solvents, optimizes the extraction method and solvent, and obtains a chromatogram with a large amount of information and high component content. The high-performance liquid chromatography fingerprint detection method provided by the present invention has good system adaptability, strong specificity, high precision, good stability, and strong repeatability, which meets the requirements for constructing fingerprints, is conducive to more comprehensive and effective control of the quality of clinical medication of Xihuang Capsules, and better guarantees its safety and efficacy. It can be applied to the quality control of Xihuang Capsules, and is of great significance to the identification of components, quality evaluation, and formulation of quality standards of Xihuang Capsules. The fingerprint of Xihuang Capsules established by the method provided by the present invention has a total of 13 characteristic common peaks, and 7 characteristic peaks are identified. It can effectively characterize the quality of Xihuang Capsules, objectively reflect the order and relationship of each fingerprint characteristic peak, and focus on the overall appearance characteristics. It can avoid the one-sidedness of judging the quality of Xihuang Capsules due to the determination of individual chemical components, and reduce the possibility of artificial processing to meet quality standards. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is the chromatogram of mixed standard product 1 of the present invention.
[0022] Figure 2 This is the chromatogram of mixed standard product 2 of the present invention.
[0023] Figure 3 These are the fingerprints of 11 batches of test samples of Xihuang Capsule of the present invention.
[0024] Figure 4 It is the mass spectrum of the myrrhone reference substance of the present invention.
[0025] Figure 5 The figure is the mass spectrum of the sandarac pimaric acid reference substance of the present invention.
[0026] Figure 6 It is the mass spectrum of the quassin reference substance of the present invention.
[0027] Figure 7 It is the mass spectrum of the musk ketone reference substance of the present invention.
[0028] Figure 8 It is the mass spectrum of the 11-carbonyl-β-boswellic acid reference substance of the present invention.
[0029] Fig. 9 It is the mass spectrum of the 11-carbonyl-β-acetylboswellic acid reference substance of the present invention.
[0030] Fig.10 The mass spectrum of the acetyl-11α-methoxy-β-boswellic acid reference substance of the present invention. DETAILED DESCRIPTION
[0031] In order to further understand the present invention, the present invention is described below in conjunction with embodiments. These descriptions are only to further explain the features and advantages of the present invention and are not intended to limit the claims of the present invention.
[0032] 1. A method for constructing a fingerprint of Xihuang Capsule, comprising the following steps:
[0033] S1. Preparation of Xihuang Capsule Test Solution:
[0034] Accurately weigh the contents of Xihuang Capsules from different batches, place them in a stoppered conical flask, add methanol-chloroform-phosphoric acid solution, perform ultrasonic extraction, and filter the filtrate through a 0.45 μm microporous filter membrane to obtain the Xihuang Capsules test solution;
[0035] S2. Preparation of standard solution:
[0036] Weigh cholic acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and mysabolone accurately, respectively, place them in a volumetric flask, and dilute to the mark with ethanol to obtain a mixed standard solution 1; weigh quassin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandarac pimaric acid accurately, place them in a volumetric flask, dilute to the mark with methanol, and shake well to obtain a mixed standard solution 2;
[0037] S3, accurately pipette the test solution of S1 and the mixed standard solution 1 and mixed standard solution 2 of S2, inject them into the high performance liquid chromatograph, and record the chromatogram;
[0038] S4, export the chromatogram of the Xihuang Capsule test solution obtained in S3, and import it into the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System 2004A; select the chromatographic peaks existing in the chromatograms of different batches of Xihuang Capsule as common peaks, there are 13 peaks in total, generate the reference fingerprint of Xihuang Capsule by the average value calculation method, calculate the relative retention time and relative peak area of each common peak; and mark the chemical composition of the peak in the reference fingerprint according to the retention time of the chromatograms of the mixed standard solution 1 and the mixed standard solution 2; generate the common chromatographic peak pattern using the reference fingerprint R, analyze and calculate the similarity between the chromatograms of each batch of Xihuang Capsule and the common chromatographic peak, and confirm the reliability of the chromatograms of each batch of Xihuang Capsule test solution;
[0039] S5. Compare the chromatogram of the Xihuang Capsule test solution obtained in S3 with the chromatograms of the mixed standard solution 1 and the mixed standard solution 2, identify that peak 3 in the Xihuang Capsule spectrum is mysabolone; peak 4 is sandarapimaric acid; peak 8 is quassin; peak 10 is musk ketone; peak 11 is 11-carbonyl-β-boswellic acid; peak 12 is 11-carbonyl-β-acetylboswellic acid; peak 13 is acetyl-11α-methoxy-β-boswellic acid, and obtain the fingerprint spectrum of Xihuang Capsule.
[0040] Among them, the method for preparing the test solution of Xihuang Capsules in S1 is preferably: accurately weigh 240 mg of the contents of 11 batches of Xihuang Capsules respectively, place them in a 250 mL stoppered conical flask, add 100 mL of [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution, ultrasonically extract for 30 minutes, and pass the filtrate through a 0.45 μm microporous filter membrane to obtain the test solution.
[0041] The method for preparing the standard solution in S2 is preferably: respectively accurately weighing bile acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and mysabolone, placing them in a volumetric flask, and diluting to the mark with ethanol to obtain a mixed standard solution 1; accurately weighing quasin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandarac pimaric acid, placing them in a volumetric flask, diluting to the mark with methanol, and shaking to obtain a mixed standard solution 2. The prepared mixed standard solution contains bile acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, mysabolone, quasin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandarac pimaric acid. The concentrations of acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandaracopimaric acid were 200 μg / mL, 200 μg / mL, 200 μg / mL, 40 μg / mL, 150 μg / mL, 150 μg / mL, 100 μg / mL, 100 μg / mL, 100 μg / mL, 100 μg / mL, and 150 μg / mL, respectively.
[0042] The liquid chromatography conditions in S3 are as follows: chromatographic column: Hypersil C18 ODS (4.6×250mm×5μm); mobile phase: methanol (A)-0.08% phosphoric acid (B)-acetonitrile (C), gradient elution; UV-visible absorption detector with multi-wavelength switching detection, detection wavelength: 0-15min: 254nm, 15-45min: 249nm, 45-90min: 239nm, 90-110min: 210nm; column temperature: 27°C; flow rate: 0.6mL / min; injection volume: 20μL; elution program is as shown in Table 1.
[0043] Table 1 Liquid chromatography elution program
[0044]
[0045] 2. Optimization process of fingerprint detection:
[0046] S1. Optimization of sample solution preparation:
[0047] The present invention experimentally investigates different extraction methods (ultrasound, reflux, and immersion), and the results show that the spectrum components obtained by ultrasonic extraction are relatively comprehensive and have good separation, so the ultrasonic extraction method is adopted;
[0048] The invention compares the extraction effects of different extraction solvents ([acetonitrile-chloroform (1:3)]-phosphoric acid (100:0.2) solution, methanol-chloroform (1:3) solution, [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution). The results show that when [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution is used as the extraction solvent, the chromatogram of the extract has the most information and the highest component content, so [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution is selected for extraction;
[0049] S2. Optimize the chromatographic conditions:
[0050] The present invention uses an ultraviolet-visible absorption detector to investigate the detection wavelength, extracts chromatograms at 254nm, 249nm, 239nm, and 210nm, and finds that the detection wavelength conditions are: 0-15min, 254nm; 15-45min, 249nm; 45-90min, 239nm; 90-110min, when the chromatogram contains the most comprehensive information and the baseline is stable, so this method is selected as the detection wavelength condition.
[0051] The present invention screened the flow rates (0.6 mL / min, 0.8 mL / min, 1.0 mL / min) and found that the peak was best and the separation was best when the flow rate was 0.6 mL / min, so the flow rate was kept at 0.6 mL / min.
[0052] The present invention screened the column temperature (25°C, 27°C, 30°C), and found that when the column temperature was maintained at 27°C, the peak elution was optimal and the separation effect of each component was better, so the column temperature was finally selected to be 27°C.
[0053] The present invention compares the elution effects of multiple different elution systems under different gradients, including methanol-water, acetonitrile-water, methanol-0.3% phosphoric acid-water, acetonitrile-0.1% phosphoric acid-water, methanol-0.1% phosphoric acid-acetonitrile, and methanol-0.08% phosphoric acid-acetonitrile. The results show that when methanol-0.08% phosphoric acid-acetonitrile is used as the mobile phase, the separation effect of the components in the Xihuang capsule is better, so methanol-0.08% phosphoric acid-acetonitrile is finally selected as the mobile phase.
[0054] After determining the optimal mobile phase composition, the present invention screens the optimal gradient elution program through a large number of experiments. The experiments show that when 0-15min methanol volume 54%→65%, 0.08% phosphoric acid volume 36%→25%; 15-45min methanol volume 65%→78%, 0.08% phosphoric acid volume 25%→12%; 45-55min methanol volume 78%→80%, 0.08% phosphoric acid volume 12%→10%; 55-65min methanol volume 80%→82%, 0.08% phosphoric acid volume 10%→8%; 65-75min methanol volume 82%→84%, 0.08% phosphoric acid volume 8%→6%; 75-90min methanol volume 84%→86%, 0.08% phosphoric acid volume 6%→4%; 90-100min methanol volume 86%→88%, 0.08% phosphoric acid volume 4%→2%; 100-110min Good separation of the chromatographic peaks in the chromatogram can be achieved when the volume of methanol is 88%→90% and the volume of 0.08% phosphoric acid is 2%→0%.
[0055] The embodiments of the present invention are described in detail below with reference to the examples. If no specific conditions are specified in the examples, the experiments are carried out according to conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0056] The instruments and reagents used in the embodiments are as follows:
[0057] Experimental equipment
[0058] 1. Instruments as shown in Table 2
[0059] Table 2 Instruments used in the present invention
[0060]
[0061]
[0062] 2. Drugs and reagents
[0063] The batch numbers of 11 batches of Xihuang Capsules samples are shown in Table 3.
[0064] Table 3 Xihuang capsule sample batch number of the present invention
[0065]
[0066] Reference substances: bile acid reference substance (batch number LY0307); hyodeoxycholic acid (batch number LY0686); deoxycholic acid reference substance (batch number LY0306); bilirubin reference substance (batch number LY0305); musk ketone reference substance (batch number LY0810); bisabolone reference substance (batch number PCS1410); sandarac pimaric acid reference substance (batch number R19618); quassin reference substance (batch number BTQ509400); 11-carbonyl-β-boswellic acid reference substance (batch number LY0864); 11-carbonyl-β-acetylboswellic acid reference substance (batch number DS1195); acetyl 11α-methoxy-β-boswellic acid reference substance (batch number HA015687). All the above reference substances were purchased from China Food and Drug Inspection Institute; methanol (analytical grade); phosphoric acid (analytical grade); acetonitrile (chromatographic grade).
[0067] Embodiment 1 A method for constructing a fingerprint of Xihuang Capsule comprises the following steps:
[0068] S1. Preparation of Xihuang Capsule Test Solution:
[0069] Take 240 mg of the contents of Xihuang Capsules from batch 11 and place them in a 250 mL stoppered conical flask, add 100 mL of [methanol-chloroform (1:3)]-phosphoric acid (100:0.2) solution, extract with ultrasound for 30 min, and filter the filtrate through a 0.45 μm microporous filter membrane to obtain the test solution;
[0070] S2. Preparation of standard solution:
[0071] The cholic acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, and mysaphorone were accurately weighed, placed in a volumetric flask, and diluted to the mark with ethanol to obtain a mixed standard solution 1; the quassin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandarac acid were accurately weighed, placed in a volumetric flask, diluted to the mark with methanol, and shaken to obtain a mixed standard solution 2. The concentrations of cholic acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone, mysaphorone, quassin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid, and sandarac acid in the prepared mixed standard solution were 200 μg / mL, 200 μg / mL, 200 μg / mL, 40 μg / mL, 50 μg / mL, 70 μg / mL, 100 μg / mL, 150 μg / mL, 160 μg / mL, 170 μg / mL, 180 μg / mL, 190 μg / mL, 200 μg / mL, 250 μg / mL, 260 μg / mL, 270 μg / mL, 280 μg / mL, 290 μg / mL, 300 μg / mL, 310 μg / mL, 310 μg / mL, 320 μg / mL, 330 μg / mL, 340 μg / mL, 350 μg / mL, 360 μg / mL, 370 μ 150μg / mL, 150μg / mL, 100μg / mL, 100μg / mL, 100μg / mL, 100μg / mL, 150μg / mL.
[0072] S3. Accurately pipette 11 batches of Xihuang Capsule test solution and standard solution respectively, inject into high performance liquid chromatograph, and record chromatograms; liquid chromatography conditions are as follows: chromatographic column: Hypersil C18 ODS (4.6×250 mm×5μm); mobile phase: methanol (A)-0.08% phosphoric acid (B)-acetonitrile (C), gradient elution; UV-visible absorption detector with multi-wavelength switching detection, detection wavelength: 0-15min: 254nm; 15-45 min: 249nm; 45-90min: 239nm; 90-110min: 210nm; column temperature: 27℃; flow rate: 0.6mL / min; injection volume: 20μL; elution program is as shown in Table 1.
[0073] S4, exporting the chromatograms of the 11 batches of Xihuang Capsule test solution obtained in S3, and importing them into the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System 2004A; selecting the chromatographic peaks existing in the chromatograms of the 11 batches of Xihuang Capsule as common peaks; generating the reference fingerprint spectrum R of Xihuang Capsule by the average value calculation method, calculating the relative retention time and relative peak area of each common peak; and marking the chemical composition of the peak in the reference fingerprint spectrum according to the retention time of the chromatogram of the standard solution;
[0074] S5, the chromatogram of the Xihuang capsule test solution obtained in S3 ( Figure 3 ) and standard solution chromatogram ( Figure 1 and Figure 2 ) for comparison and combined with Figure 4-Figure 10, identified the main components, and compared the chromatographic peaks 3, 4, 8, 10, 11, 12, and 13 in Xihuang Capsule, which were: mysabolone (retention time 18.834min), sandaracopimaric acid (retention time 22.316min), quassin (retention time 33.579min), musk ketone (retention time 44.632min), 11-carbonyl-β-boswellic acid (retention time 49.086min), 11-carbonyl-β-acetylboswellic acid (retention time 53.643min), acetyl-11α-methoxy-β-boswellic acid (retention time 58.967min), and the fingerprint of Xihuang Capsule was obtained.
[0075] At the same time, the present invention uses the automatically generated control fingerprint spectrum R to generate a common chromatographic peak pattern, and the analysis and calculation show that the common chromatographic peaks of 11 batches of Xihuang Capsules have relatively good similarity, indicating that the fingerprint spectrum of Xihuang Capsules established by this method can well detect the quality of Xihuang Capsules and 11 batches of Xihuang Capsules. The results are shown in Table 4.
[0076] Table 4 Similarity between each batch of samples and the common chromatographic peak pattern
[0077]
[0078]
[0079] Example 2 Methodological study of fingerprint detection method:
[0080] S1. Precision study
[0081] The standard solution prepared by the method of Example 1 was taken and analyzed according to the detection method of Example 1. The sample was injected in parallel 6 times with an injection volume of 20 μL. The peak area and retention time were analyzed and the RSD value was calculated. The results are shown in Table 5. The results show that the parallel injection precision of the device is good.
[0082] Table 5 Peak area and retention time of precision study
[0083]
[0084] S2. Stability study
[0085] 1.25 g of the contents of Xihuang Capsule was taken and a test solution was prepared according to the method of Example 1. The test solution was analyzed according to the detection method of Example 1, and the sample was injected at different times of 0, 2, 6, 12, 18, and 24 h. The injection volume was 20 μL. Myrrhone, sandarac acid, quassin, musk ketone, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, and acetyl-11α-methoxy-β-boswellic acid were used as reference peaks. The peak area and retention time of the common peaks of the HPLC fingerprint of the sample were analyzed and the RSD value was calculated. The results are shown in Table 6, indicating that the chromatographic peaks of the Xihuang Capsule test solution within 24 h had almost no change and good stability.
[0086] Table 6 Peak areas and retention times for stability studies
[0087]
[0088] S3. Reproducibility study
[0089] Six batches of sample solutions were prepared according to the test solution method in Example 1, with reference to the chromatographic conditions of Example 1, the injection volume was 20 μL, and mysabolone, sandaracopimaric acid, quassin, musk ketone, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, and acetyl-11α-methoxy-β-boswellic acid were used as reference peaks. The peak areas and retention times of the common peaks in the HPLC fingerprints of the samples were analyzed and the RSD values were calculated. The results are shown in Table 4. The results show that the sample chromatographic peaks have good reproducibility and the method has good repeatability.
[0090] Table 7 Peak area and retention time of repeatability study
[0091]
[0092] The above experimental results indicate that the fingerprint construction method of Xihuang Capsules provided by the present invention has the characteristics of good stability, high precision and good repeatability, and can comprehensively and objectively evaluate the quality of Xihuang Capsules, providing quality assurance for clinical efficacy.
[0093] The above embodiments are only exemplary embodiments of the present invention and are not intended to limit the present invention. The protection scope of the present invention is defined by the claims. The above contents are only used as examples and explanations of the concept of the present invention. Various modifications or supplements made by technicians in the technical field to the described specific embodiments or replacements in similar ways shall fall within the protection scope of the present invention as long as they do not deviate from the concept of the invention or exceed the scope defined by the claims.
Claims
1. A method for constructing a fingerprint of Xihuang Capsule, characterized in that: The following steps are involved: S1. Take the contents of Xihuang Capsules, add methanol-chloroform-phosphoric acid solution, and perform ultrasonic extraction to obtain the Xihuang Capsules test solution; S2, take bile acid, hyodeoxycholic acid, deoxycholic acid, bilirubin, musk ketone and bisabolone, dissolve in ethanol, and obtain mixed standard solution 1; take quassin, 11-carbonyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, acetyl-11α-methoxy-β-boswellic acid and sandarac pimaric acid, dissolve in methanol, and obtain mixed standard solution 2; S3, injecting the Xihuang Capsule test solution, mixed standard solution 1 and mixed standard solution 2 into a high performance liquid chromatograph, respectively, performing chromatographic analysis, and recording corresponding chromatograms; S4. Constructing a fingerprint of Xihuang Capsule according to the chromatogram of the Xihuang Capsule test solution and the chromatograms of the mixed standard solution 1 and the mixed standard solution 2 obtained in S3; In S1, in the methanol-chloroform-phosphoric acid solution, the volume ratio of methanol to chloroform is 1:3, and the volume ratio of the total amount of methanol and chloroform to phosphoric acid is 100:0.2; In S3, the chromatographic column used in the high performance liquid chromatograph was Hypersil C18 ODS, the mobile phase used in the chromatographic analysis was methanol-0.08% phosphoric acid-acetonitrile, and the UV-visible absorption detector was used for multi-wavelength switching detection. The detection wavelengths were: 0-15 min: 254 nm, 15-45 min: 249 nm, 45-90 min: 239 nm, 90-110 min: 210 nm, the gradient elution program is: 0-15 min methanol volume 54% → 65%, 0.08% phosphoric acid volume 36% → 25%; 15-45 min methanol volume 65% → 78%, 0.08% phosphoric acid volume 25% → 12%; 45-55 min methanol volume 78% → 80%, 0.08% phosphoric acid volume 12% → 10%; 55-65 min methanol volume 80% → 82%, 0.08% phosphoric acid volume 10% → 8%; 65-75 min methanol volume 82% → 84%, 0.08% phosphoric acid volume 8% → 6%; 75-90 min methanol volume 84% → 86%, 0.08% phosphoric acid volume 6% → 4%; 90-100 min methanol volume 86% → 88%, 0.08% phosphoric acid volume 4% → 2%; 100-110 min methanol volume 88% → 90%, 0.08% phosphoric acid volume 2% → 0%.
2. The method for constructing the fingerprint of Xihuang Capsule according to claim 1, characterized in that: S4 specifically includes: importing the chromatograms of different batches of Xihuang capsule test solutions into the Chinese medicine chromatographic fingerprint similarity evaluation system 2004A, selecting the chromatographic peaks existing in the chromatograms of different batches of Xihuang capsule as common peaks, generating the reference fingerprint of Xihuang capsule by the average value calculation method, calculating the relative retention time and relative peak area of each common peak; and marking the chemical composition of each common peak in the reference fingerprint according to the retention time of the chromatograms of the mixed standard solution 1 and the mixed standard solution 2; generating the common chromatographic peak pattern by using the reference fingerprint R, analyzing and calculating the similarity between the chromatograms of each batch of Xihuang capsule and the common chromatographic peak, and confirming the reliability of the chromatograms of each batch of Xihuang capsule test solutions; The chromatogram of the test solution of Xihuang Capsule obtained in S3 was compared with the chromatograms of mixed standard solution 1 and mixed standard solution 2, and peak 3 in the chromatogram was identified as mysabolone; peak 4 was sandarapimaric acid; peak 8 was quassin; peak 10 was musk ketone; peak 11 was 11-carbonyl-β-boswellic acid; peak 12 was 11-carbonyl-β-acetylboswellic acid; peak 13 was acetyl-11α-methoxy-β-boswellic acid, and the fingerprint of Xihuang Capsule was obtained.
